PRESS RELEASE, March 3, 2020
AlzeCure Pharma AB (publ) (FN STO: ALZCUR), a pharmaceutical company developing a broad portfolio of drug candidates for diseases affecting the central nervous system, with projects in both Alzheimer’s disease and pain, today announced that An van Es-Johansson is joining the company’s management team. In doing so, she is directly involved in the development of AlzeCure’s candidate portfolio. She has resigned from AlzeCure Pharma AB’s Board of Directors as a result of the new position.
An van Es-Johansson will as of today be part of AlzeCure Pharma’s management team as Chief Medical Officer and Head of Development. She thus leaves AlzeCure Pharma’s board with immediate effect.
“With An’s solid background from the pharmaceutical industry within clinical development and medical affairs, this change strengthens AlzeCure in a period when the company is developing and preparing to increase the number of clinical trials during the year, in line with previously communicated plans,” said Martin Jönsson, CEO of AlzeCure Pharma. “An will play a central role in the company’s development and it feels great to have such an experienced and knowledgeable clinician on the team.”
An van Es-Johansson holds a medical degree from the Erasmus University in Rotterdam (The Netherlands) and has previously held various senior positions within clinical development, medical affairs, business development and marketing at Sobi, Eli Lilly, Roche, Pharmacia & Upjohn and biotech companies in the US, Holland, Switzerland and Sweden. She is an entrepreneur and also a board member of BioInvent, Agendia, Savara Pharmaceuticals, PLUS Therapeutics and Medivir.
The information was submitted for publication, through the agency of the contact person set out below at 2.00 pm CET on March 3, 2020.
For more information, please contact
Martin Jönsson, CEO
Tel: +46 (0)70-786 94 43
E-mail: martin.jonsson@alzecurepharma.com
About AlzeCure Pharma
AlzeCure Pharma AB is a Swedish pharmaceutical company engaged in innovative drug research with a primary focus on Alzheimer’s disease and pain. The company is listed on Nasdaq First North Premier Growth Market and is developing five drug candidates based on the two research platforms, NeuroRestore® and Alzstatin®. The NeuroRestore platform comprises symptom-relieving drug candidates while Alzstatin comprises disease modifying and preventive drug candidates. A diversified portfolio of drug candidates that act on central signaling pathways in the brain also opens up for other indications such as cognitive dysfunctions in traumatic brain injury (TBI), sleep apnea and Parkinson’s disease. The company also has two projects in the field of pain, TrkA-NAM and VR1. FNCA Sweden AB, +46(0)8-528 00 399, info@fnca.se, is the company’s certified adviser. For further information, please visit our website at www.alzecurepharma.se